Novartis will help to patients with multiple sclerosis


Date: 20.04.2021

Novartis announced that the European Commission has approved Kesimpta® (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features.

Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that has shown superior efficacy with a similar safety profile compared with teriflunomide, a first-line treatment in MS2. Kesimpta is the first B-cell therapy that can be self-administered once-monthly at home via the Sensoready® autoinjector pen and can be a first-choice treatment option for patients with RMS3.

“With more than 1 million people living with MS – an incurable condition so far - in Europe, it is encouraging to see that research continues to develop more treatments. We welcome the approval from the European Medicines Agency that gives another treatment option for people living with RMS”, said Pedro Carrascal, President of the European Multiple Sclerosis Platform (EMSP).

Based on:

#News #Health #Medical #Novartis #Whealthnews

Views: 44

Leave a request

Select option
Thank you, application submitted.